Eosinophilic pleural effusion associated with the addition of sodium valproate

Journal of Clinical Psychopharmacology

Volumn 29, Issue 3, 2009, Pages 310-311

  Fernández Pérez, Ramón ^a   Álvarez Dobaño, José Manuel ^a   Suárez Antelo, Juan ^a   Codesido Barcala, Rosario ^a   Carballal Calvo, Fernando ^a   Arrojo Romero, Manuel ^a   De Leon, Jose ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b EASTERN STATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPERIDEN; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; OLANZAPINE; VALPROIC ACID;

ADULT; ANAMNESIS; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HEBEPHRENIA; HUMAN; LETTER; PLEURA EFFUSION; PRIORITY JOURNAL; THORACOCENTESIS; THORAX RADIOGRAPHY;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG THERAPY, COMBINATION; EOSINOPHILIA; FEMALE; HUMANS; MIDDLE AGED; PLEURAL EFFUSION; VALPROIC ACID;

EID: 67649243655     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181a2e1cf     Document Type: Letter

References (20)

1. Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med. 2004;25:141-153.
2. Bullington W, Sahn SA, Judson MA. Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature. Am J Med Sci. 2007;333:290-292.
3. Catalán Alcántara A, Sánchez Pérez M, Domezain del Campo M, et al. Eosinophilic pleural effusion secondary to treatment with valproic acid [letter]. Actas Esp Psiquiatr. 2005;33:401-402.
4. Chiles C, van Wattum PJ. Pleural fluid eosinophilia with combined pharmacotherapy [letter]. Psychosomatics. 2003;44:436-437.
5. Kaufman J, O'Shaughnessy IM. Eosinophilic pleural effusion associated with valproic acid administration. South Med J. 1995;88:881-882.
6. Kravetz JD, Federman DG. Valproic acid-induced eosinophilic pleural effusion. South Med J. 2003;96:803-806.
7. Tonnelier JM, Mocquard Y, Broch C, et al. Febrile pleuropericarditis during valproic acid treatment [letter]. Presse Med. 2001;30:62-63.
8. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy. 2007;27:1425-1439.
9. Bhatti MA, Zander J, Reeve E. Clozapine-induced pericarditis, pericardial tamponade, polyserositis, and rash [letter]. J Clin Psychiatry. 2005;66:1490-1491.
10. Chatterjee A, Safferman AZ. Cellulitis, eosinophilia, and unilateral pleural effusion associated with clozapine treatment [letter]. J Clin Psychopharmacol. 1997;17:232-323.
11. Stanislav SW, Gonzalez-Blanco M. Papular rash and bilateral pleural effusion associated with clozapine [letter]. Ann Pharmacother. 1999;33:1008-1009.
12. Schonfeldt-Lecuona C, Conneman BJ. Sweet's syndromeandpolyserositiswithclozapine [letter]. Am J Psychiatry.2002;159: 1947.
13. Eymin G, Andresen M, Godoy J, et al. Malignant neuroleptic syndrome and polyserositis associated to clozapine use: report of one case. Rev Med Chil. 2005;133:1225-1228.
14. Thompson J, Chengappa KN, Good CB, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol. 1998;13:95-98.
15. Catalano G, Catalano MC, Frankel Wetter RL. Clozapine induced polyserositis. Clin Neuropharmacol. 1997;20:352-356.
16. Daly JM, Goldberg RJ, Braman SS. Polyserositis associated with clozapine treatment [letter]. Am J Psychiatry. 1992;149:1274-1275.
17. Lim A, Sivakumaran P, Israel M. Clozapine-associated polyserositis [letter]. N Z Med J. 2003;116:U651.
18. Murko A, Clarke S, Black DW. Clozapine and pericarditis with pericardial effusion [letter]. Am J Psychiatry. 2002;159:494.
19. Boot E, de Haan L, Guzelcan Y, et al. Pericardial and bilateral pleural effusion associated with clozapine treatment [letter]. Eur Psychiatry. 2004;19:65.
20. Diaz FJ, Santero V, Spina E, et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry. 2008;41:81-91.